LT5079B - Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai - Google Patents

Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai Download PDF

Info

Publication number
LT5079B
LT5079B LT2003009A LT2003009A LT5079B LT 5079 B LT5079 B LT 5079B LT 2003009 A LT2003009 A LT 2003009A LT 2003009 A LT2003009 A LT 2003009A LT 5079 B LT5079 B LT 5079B
Authority
LT
Lithuania
Prior art keywords
viruses
viral
fragments
virus
treatment
Prior art date
Application number
LT2003009A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2003009A (en
Inventor
Olaf Weber
Tobias Schlapp
Angela Siegling
Andreas Knorr
Claudia Hirth-Dietrich
Gudrun Theiss
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122451A external-priority patent/DE10122451A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of LT2003009A publication Critical patent/LT2003009A/xx
Publication of LT5079B publication Critical patent/LT5079B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LT2003009A 2000-07-11 2003-02-03 Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai LT5079B (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033582 2000-07-11
DE10122451A DE10122451A1 (de) 2000-07-11 2001-05-09 Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs

Publications (2)

Publication Number Publication Date
LT2003009A LT2003009A (en) 2003-08-25
LT5079B true LT5079B (lt) 2003-12-29

Family

ID=26006335

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2003009A LT5079B (lt) 2000-07-11 2003-02-03 Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai

Country Status (36)

Country Link
US (1) US6685950B2 (pl)
EP (1) EP1303286B1 (pl)
JP (1) JP5037775B2 (pl)
CN (1) CN1455674B (pl)
AR (1) AR029954A1 (pl)
AT (1) ATE324115T1 (pl)
AU (2) AU7063101A (pl)
BG (1) BG107448A (pl)
CA (1) CA2415397C (pl)
CY (1) CY1105408T1 (pl)
CZ (1) CZ200371A3 (pl)
DE (1) DE50109630D1 (pl)
DK (2) DK1303286T3 (pl)
EE (1) EE200300018A (pl)
ES (1) ES2262663T3 (pl)
FI (1) FI20030037L (pl)
GB (1) GB2381454B8 (pl)
HK (1) HK1054329B (pl)
HR (1) HRP20030096A2 (pl)
HU (1) HUP0400479A3 (pl)
IL (1) IL153643A0 (pl)
LT (1) LT5079B (pl)
LU (1) LU90997B1 (pl)
LV (1) LV12990B (pl)
MA (1) MA26927A1 (pl)
MX (1) MXPA03000279A (pl)
NO (1) NO20030082D0 (pl)
NZ (1) NZ523534A (pl)
PL (1) PL366397A1 (pl)
PT (1) PT1303286E (pl)
RU (1) RU2003104525A (pl)
SE (1) SE0300034L (pl)
SI (1) SI21122A (pl)
SK (1) SK362003A3 (pl)
UY (1) UY26832A1 (pl)
WO (1) WO2002004002A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
NZ512341A (en) 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
EP1499355A4 (en) * 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
EP1420822B2 (en) * 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
AU2003264144C1 (en) * 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
JP4897677B2 (ja) * 2004-07-13 2012-03-14 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト Ｈｉｖ／ａｉｄｓの処置用の他の抗ウイルス剤と組み合わせたパラポックスウイルス
PL1951274T3 (pl) * 2005-11-24 2010-05-31 Aicuris Gmbh & Co Kg Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka
JP5004990B2 (ja) * 2009-03-31 2012-08-22 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504940A1 (de) 1984-02-17 1985-10-31 Mayr, Anton, Prof. Dr.med.vet. Dr.h.c.mult., 8000 München Multipotente paramunitaetsmediatoren, verfahren zu ihrer herstellung und diese mediatoren enthaltende arzneimittel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
AU718141B2 (en) * 1996-02-28 2000-04-06 Bayer Healthcare Ag Parapoxviruses which contain foreign DNA, their preparation and their use in vaccines
AU2182697A (en) * 1996-03-29 1997-10-22 University Of Otago Parapoxvirus vectors
ES2125846T3 (es) * 1996-04-15 2001-12-16 Anton Prof Dr Med Vet Dr Mayr Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.
SE9700617D0 (sv) * 1997-02-21 1997-02-21 Kjell Alving New composition
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
WO2000025805A1 (en) * 1998-11-02 2000-05-11 Ludwig Institute For Cancer Research Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504940A1 (de) 1984-02-17 1985-10-31 Mayr, Anton, Prof. Dr.med.vet. Dr.h.c.mult., 8000 München Multipotente paramunitaetsmediatoren, verfahren zu ihrer herstellung und diese mediatoren enthaltende arzneimittel

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DHAWAN, S. ET AL.: "Interferon gamma inhibits HIV-induced invasiveness of Monocytes", J. LEUKOCYTE BIOLOGY, 1995, pages 713 - 716
GUIDOTTI, L. G. ET AL.: "Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice", PROC. NATL. ACAD. SCI. USA, 1994, pages 3764 - 3768
J. F. BROMBERG, C. M. HORVATH, Z. L. WEN, R.: "Transcriptionally active statl is required for the antiproliferative effects of both interferon alpha and interferon gamma", PNAS, 1996, pages 7673 - 7678
LUCA G. GUIDOTTI ET AL.: "Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver", PROC. NATL. ACAD. SCI. USA, 1996, pages 4589 - 4594
M. KLOUCHE, H. KIRCHNER, F. HOLZEL: "Antiproliferative effects of interferon gamma in combination with alpha-difluoromethylornithine on human carcinoma cell cultures", J. CANCER RESEARCH AND CLINICAL ONCOLOGY, 1994, pages 706
P. LUCIN, S. JONJIC, M. MESSERLE, B. POLIC, H: "Late-Phase inhibition of murine cytomegalovirus replication by synergistic action of interferon gamma and tumor necrosis factor alpha", J. GEN. VIROL, 1994, pages 101 - 110
SMITH, R. M. WOLCOTT, R. CHERVENAK, S. R. JEN: "Control of acute cutaneous herpes-simplex virus-Infection - T-cell mediated viral clearance is dependent upon interferon gamma", VIROLOGY, 1994, pages 76 - 88
STEINMASSL, G., G. WOLF: "Bildung von Interleukin 2 und Interferon- durch mononukleäre Leukozyten des Schweines nach in vitro-Stimulation mit verschiedenen Viruspräparaten", J. VET. MED., 1990, pages 321 - 331

Also Published As

Publication number Publication date
ATE324115T1 (de) 2006-05-15
GB2381454A (en) 2003-05-07
AR029954A1 (es) 2003-07-23
MXPA03000279A (es) 2004-04-05
EE200300018A (et) 2004-10-15
DK200300015A (da) 2003-03-07
PL366397A1 (pl) 2005-01-24
IL153643A0 (en) 2003-07-06
HK1054329B (zh) 2005-10-07
MA26927A1 (fr) 2004-12-20
NZ523534A (en) 2005-02-25
AU7063101A (en) 2002-01-21
DE50109630D1 (de) 2006-06-01
FI20030037A7 (fi) 2003-03-10
PT1303286E (pt) 2006-08-31
GB2381454B8 (en) 2007-10-23
CN1455674A (zh) 2003-11-12
LU90997B1 (en) 2003-01-08
EP1303286A2 (de) 2003-04-23
NO20030082L (no) 2003-01-08
GB2381454A8 (en) 2007-10-23
AU2001270631B2 (en) 2005-07-07
HUP0400479A3 (en) 2006-02-28
NO20030082D0 (no) 2003-01-08
HRP20030096A2 (en) 2005-02-28
CZ200371A3 (cs) 2003-04-16
CN1455674B (zh) 2019-03-29
WO2002004002A3 (de) 2002-10-31
US6685950B2 (en) 2004-02-03
JP5037775B2 (ja) 2012-10-03
RU2003104525A (ru) 2004-06-27
HK1054329A1 (en) 2003-11-28
SE0300034D0 (sv) 2003-01-10
CA2415397C (en) 2011-04-26
ES2262663T3 (es) 2006-12-01
SI21122A (sl) 2003-08-31
LT2003009A (en) 2003-08-25
WO2002004002A2 (de) 2002-01-17
FI20030037L (fi) 2003-03-10
GB2381454B (en) 2004-11-24
DK1303286T3 (da) 2006-08-28
SK362003A3 (en) 2003-07-01
US20030021769A1 (en) 2003-01-30
BG107448A (bg) 2003-11-28
SE0300034L (sv) 2003-03-03
JP2004517807A (ja) 2004-06-17
CA2415397A1 (en) 2002-01-17
CY1105408T1 (el) 2010-04-28
HUP0400479A2 (hu) 2004-06-28
LV12990B (en) 2003-08-20
GB0302630D0 (en) 2003-03-12
UY26832A1 (es) 2002-01-31
EP1303286B1 (de) 2006-04-26

Similar Documents

Publication Publication Date Title
US6685950B2 (en) Methods of treating viral infections
Sidwell et al. Viruses of the Bunya-and Togaviridae families: potential as bioterrorism agents and means of control
Zawatzky et al. The Role of Interferon in the Resistance of CS7BL/6 Mice to Various Doses of Herpes Simplex Virus Type 1
KR20180021083A (ko) 바이러스성 색전술을 위한 조성물 및 방법
Alfano et al. New players in cytokine control of HIV infection
CN111686107B (zh) 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途
Stringfellow et al. Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis
JP2012121902A (ja) 抗ウイルス薬および癌に対する医薬を製造するためのパラポックスウイルスｏｖｉｓ株の使用
Webster Virus infections in primary immunodeficiency
JP2000007578A (ja) Ｃ型肝炎ウイルスの陰性化のための投薬システム
CN118127004A (zh) 靶向HSV必需基因的gRNA、CRISPR/Cas基因编辑系统、递送系统及应用
JP2000501114A (ja) 弱毒化された非免疫原性ポックスウイルスまたはパラポックスウイルスからの多種有効性パラポックス免疫誘導剤の薬剤としての使用のための新規薬効
Kim et al. Intranasal treatment with CpG-B oligodeoxynucleotides protects CBA mice from lethal equine herpesvirus 1 challenge by an innate immune response
HK1060063A (en) Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
IL176634A (en) Monoparamunity inducers based on attenuated rabbit myxoma viruses
Sarzotti et al. LFN-γ Production in Response to Neuropathogenic Cas-Br-M Murine Leukemia Virus Infection
WO2024113302A1 (zh) 靶向HSV必需基因的gRNA、CRISPR/Cas基因编辑系统、递送系统及应用
CN118252916A (zh) 一种抑制不同类型猪繁殖与呼吸综合症病毒感染的14-3-3γ蛋白及其应用
Flisiak et al. Effect of lamivudine treatment on plasma levels of transforming growth factor beta 1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B
Frank et al. Outbreak of hepatitis B virus infection in an ambulatory haemodialysis clinic in Germany
CN115671145A (zh) 一种用于预防和抗嗜神经性病毒感染的药物及其制备方法
WO1998037905A1 (en) Arrestable therapeutic viral agent
Francavilla et al. Category 6: Viral hepatitis: clinical aspects 141

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: AICURIS GMBH & CO. KG, DE

Effective date: 20070620

TC9A Change of representative
MM9A Lapsed patents

Effective date: 20140711